Endothelial Cell Deubiquitinase A20 Signals Repair of Lung Vascular Injury

内皮细胞去泛素酶 A20 发出肺血管损伤修复信号

基本信息

项目摘要

 DESCRIPTION (provided by applicant): Acute lung injury (ALI) is a complex inflammatory disease associated with increased lung vascular permeability and formation of protein-rich edema fluid and an infiltration of inflammatory cells in lung tissue and airspace. Reassembly of lung vascular endothelial adherens junctions (AJs) is a critical factor contributing to resolution f acute inflammatory lung injury. Expression of vascular endothelial (VE)-cadherin and the interacting endothelial protein tyrosine phosphatase (VE-PTP) at AJs is vital for endothelial barrier integrity. However, the signaling mechanisms that mediate the reassembly of endothelial AJs are poorly understood. We have identified in a genetic model of endothelial cell (EC)-restricted A20 (Tnfaip3) knockout (A20ΔEC) mice, the novel role of the ubiquitin editing function of A20 in regulating expression of VE-cadherin and VE-PTP at AJs. We made the following key observations (Supporting Data): (i) A20ΔEC mice displayed markedly reduced expression of VE- cadherin and VE-PTP at AJs; (ii) VE-cadherin and VE-PTP expression was not restored at AJs of A20ΔEC mice after endotoxin challenge; (iii) A20ΔEC mice showed persistent prolyl hydroxylase 2 (PHD2) expression and defective HIF2α expression post-endotoxin challenge. Based on these novel observations, in Aim 1, we will test the hypothesis that expression of A20 in lung ECs, downstream of TLR4 signaling, promotes the sequestration of VE-cadherin at AJs, and thus is a central feedback mechanism for stabilizing endothelial barrier and promoting resolution of lung injury. In Aim 2, we will test the hypothesis that EC-expressed A20 serves a pro-resolution function in inflammatory lung injury by down-regulating PHD2 to stabilize HIF2α and transcriptionally regulating VE-PTP expression so as to strengthen VE-cadherin function at AJs. With a better understanding of the signaling mechanisms of A20 function in lung endothelial cells, we will be in a position to identify therapeutic strategies that can target A20 function and thereby restore endothelial barrier integrity to resolve inflammatory lung injury.
 描述(由申请人提供):急性肺损伤(ALI)是一种复杂的炎性疾病,与肺血管通透性增加、富含蛋白质的水肿液形成以及肺组织和空气中炎性细胞浸润相关。肺血管内皮粘附连接(AJs)的重组是急性炎症性肺损伤(ALI)的重要因素。血管内皮(VE)-钙粘蛋白和相互作用的内皮蛋白酪氨酸磷酸酶(VE-PTP)在AJs的表达对内皮屏障的完整性至关重要。然而,介导内皮细胞AJs重组的信号转导机制知之甚少。我们已经在内皮细胞(EC)限制性A20(Tnfaip 3)敲除(A20ΔEC)小鼠的遗传模型中确定了A20的泛素编辑功能在调节AJs的VE-钙粘蛋白和VE-PTP表达中的新作用。我们进行了以下关键观察(支持性数据):(i)A20ΔEC小鼠显示AJs处VE-钙粘蛋白和VE-PTP的表达显著降低;(ii)内毒素激发后A20ΔEC小鼠AJs处VE-钙粘蛋白和VE-PTP的表达未恢复;(iii)内毒素激发后A20 ΔEC小鼠显示持续的脯氨酰羟化酶2(PHD 2)表达和缺陷的HIF 2 α表达。基于这些新的观察结果,在目标1中,我们将检验以下假设:肺EC中TLR 4信号传导下游的A20表达促进VE-钙粘蛋白在AJs的隔离,因此是稳定内皮屏障和促进肺损伤消退的中心反馈机制。在目的2中,我们将检验以下假设:EC表达的A20通过下调PHD 2以稳定HIF 2 α并转录调节VE-PTP表达以加强AJs的VE-钙粘蛋白功能,在炎性肺损伤中起到促消退作用。随着对肺内皮细胞中A20功能的信号传导机制的更好理解,我们将能够确定可以靶向A20功能的治疗策略, 从而恢复内皮屏障完整性以解决炎性肺损伤。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHINNASWAMY TIRUPPATHI其他文献

CHINNASWAMY TIRUPPATHI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHINNASWAMY TIRUPPATHI', 18)}}的其他基金

Novel E3 Ubiquitin Ligase CHFR Regulates Endothelial Barrier Integrity and Innate Immune Function
新型 E3 泛素连接酶 CHFR 调节内皮屏障完整性和先天免疫功能
  • 批准号:
    10488226
  • 财政年份:
    2021
  • 资助金额:
    $ 39.98万
  • 项目类别:
Transcription Factor Elf2 Signals Resolution of Lung Injury
转录因子 Elf2 发出肺损伤消退信号
  • 批准号:
    10363718
  • 财政年份:
    2021
  • 资助金额:
    $ 39.98万
  • 项目类别:
Novel E3 Ubiquitin Ligase CHFR Regulates Endothelial Barrier Integrity and Innate Immune Function
新型 E3 泛素连接酶 CHFR 调节内皮屏障完整性和先天免疫功能
  • 批准号:
    10297258
  • 财政年份:
    2021
  • 资助金额:
    $ 39.98万
  • 项目类别:
Transcription Factor Elf2 Signals Resolution of Lung Injury
转录因子 Elf2 发出肺损伤消退信号
  • 批准号:
    10178835
  • 财政年份:
    2021
  • 资助金额:
    $ 39.98万
  • 项目类别:
Transcription Factor Elf2 Signals Resolution of Lung Injury
转录因子 Elf2 发出肺损伤消退信号
  • 批准号:
    10586059
  • 财政年份:
    2021
  • 资助金额:
    $ 39.98万
  • 项目类别:
Endothelial TAK1 Signaling and Resolution of Pulmonary Edema in Sepsis
脓毒症肺水肿的内皮 TAK1 信号转导和解决
  • 批准号:
    9535680
  • 财政年份:
    2016
  • 资助金额:
    $ 39.98万
  • 项目类别:
Endothelial Cell Deubiquitinase A20 Signals Repair of Lung Vascular Injury
内皮细胞去泛素酶 A20 发出肺血管损伤修复信号
  • 批准号:
    9301023
  • 财政年份:
    2015
  • 资助金额:
    $ 39.98万
  • 项目类别:
TRPM2 mediates neutrophil transendothelial migration and inflammation
TRPM2介导中性粒细胞跨内皮迁移和炎症
  • 批准号:
    9260918
  • 财政年份:
    2015
  • 资助金额:
    $ 39.98万
  • 项目类别:
Ca2+ Signaling, ICAM-1 Expression, and Lung Vascular Injury
Ca2 信号传导、ICAM-1 表达和肺血管损伤
  • 批准号:
    7457949
  • 财政年份:
    2007
  • 资助金额:
    $ 39.98万
  • 项目类别:
Cell Culture and Vector Core
细胞培养和载体核心
  • 批准号:
    7457951
  • 财政年份:
    2007
  • 资助金额:
    $ 39.98万
  • 项目类别:

相似海外基金

Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
  • 批准号:
    10648387
  • 财政年份:
    2023
  • 资助金额:
    $ 39.98万
  • 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
  • 批准号:
    10720687
  • 财政年份:
    2023
  • 资助金额:
    $ 39.98万
  • 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
  • 批准号:
    10719249
  • 财政年份:
    2023
  • 资助金额:
    $ 39.98万
  • 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
  • 批准号:
    10591804
  • 财政年份:
    2023
  • 资助金额:
    $ 39.98万
  • 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
  • 批准号:
    10741574
  • 财政年份:
    2023
  • 资助金额:
    $ 39.98万
  • 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
  • 批准号:
    23K07651
  • 财政年份:
    2023
  • 资助金额:
    $ 39.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
  • 批准号:
    10679944
  • 财政年份:
    2023
  • 资助金额:
    $ 39.98万
  • 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
  • 批准号:
    10575258
  • 财政年份:
    2023
  • 资助金额:
    $ 39.98万
  • 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
  • 批准号:
    10701207
  • 财政年份:
    2023
  • 资助金额:
    $ 39.98万
  • 项目类别:
Roles of N-glycans on neutrophil beta2 integrins in progression of acute lung injury
N-聚糖对中性粒细胞β2整合素在急性肺损伤进展中的作用
  • 批准号:
    10837431
  • 财政年份:
    2023
  • 资助金额:
    $ 39.98万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了